The oncologist
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer.
Emmanuelle Samalin, Hélène Senellart, Simon Thezenas, Stéphane Jacquot, Stephen Ellis, Faiza Khemissa Akouz, Catherine Fiess, Mohamed Ramdani, Fabienne Portales, Eric Assenat, Marc Ychou, Laurent Mineur, Thibault Mazard
Published: 202610.1093/oncolo/oyag006
Abstract
BACKGROUND: Second-line FOLFOX-bevacizumab treatment is effective in metastatic colorectal cancer (mCRC) treatment after irinotecan-based chemotherapy failure. First- or second-line raltitrexed-oxaliplatin (TOMOX) treatment has an acceptable toxicity…
Preview only. Read the full abstract at the source